Positive results from COLCORONA trial show that colchicine is the only effective oral medication for treating non-hospitalized patientsMONTREAL, Jan. 22, 2021 (GLOBE NEWSWIRE) -- The Montreal Heart Institute (MHI) announced today that the COLCORONA clinical trial has provided clinically persuasive results of colchicine’s efficacy to treat COVID-19. The study results have shown that colchicine has reduced by 21% the risk of death or hospitalizations in patients with COVID-19 compared to placebo. This result obtained for the global study population of 4488 patients approached statistical significance. The analysis of the 4159 patients in whom the diagnosis of COVID-19 was proven by a naso-pharyngeal PCR test has shown that the use of colchicine was associated with statistically significant reductions in the risk of death or hospitalization compared to placebo. In these patients with a proven diagnosis of COVID-19, colchicine reduced hospitalizations by 25%, the need for mechanical ventilation by 50%, and deaths by 44%. This major scientific discovery makes colchicine the world’s first oral drug that could be used to treat non-hospitalized patients with COVID-19. “Our research shows the efficacy of colchicine treatment in preventing the ‘cytokine storm’ phenomenon and reducing the complications associated with COVID-19,” said Dr. Jean-Claude Tardif, Director of the MHI Research Center, Professor of Medicine at the Université de Montréal and Principal Investigator of the COLCORONA trial. “We are pleased to offer the first oral medication in the world whose use could have a significant impact on public health and potentially prevent COVID-19 complications for millions of patients.” Treating patients at risk of complications with colchicine as soon as the diagnosis of COVID-19 is confirmed by PCR reduces their risk of developing a severe form of the disease and, consequently, reduces the number of hospitalizations. Prescribing colchicine to patients could help alleviate the problems of hospital congestion and reduce healthcare costs here and around the world. “Our innovative research program also proves that the Montreal Heart Institute can make rapid scientific breakthroughs in a way that is economically viable for patients by repurposing existing drugs,” continued Dr. Jean-Claude Tardif. COLCORONA is a contact-less, randomized, double-blind, placebo-controlled clinical trial that took place at home. It has been conducted in Canada, the United States, Europe, South America and South Africa. It was designed to determine whether colchicine could reduce the risk of severe complications associated with COVID-19. COLCORONA was conducted among approximately 4,500 COVID-19 patients not hospitalized at the time of enrollment, with at least one risk factor for COVID-19 complications. This is the world’s largest study testing an orally administered drug in non-hospitalized patients with COVID-19. COLCORONA was coordinated by the Montreal Heart Institute’s Montreal Health Innovations Coordinating Center (MHICC), and funded by the Government of Quebec, the National Heart, Lung, and Blood Institute of the U.S. National Institutes of Health (NIH), Montreal philanthropist Sophie Desmarais, and the COVID-19 Therapeutics Accelerator, an initiative launched by the Bill & Melinda Gates Foundation, Wellcome and Mastercard. CGI, Dacima and Pharmascience of Montreal were also collaborators in the trial. The Montreal Heart Institute and its global partners would like to warmly thank the participants and researchers for their collaboration in the COLCORONA clinical trial. For more information, visit colcorona.net. About the Montreal Heart InstituteFounded in 1954, the Montreal Heart Institute constantly aims for the highest standards of excellence in the cardiovascular field through its leadership in clinical and basic research, ultra-specialized care, professional training, and prevention. It houses the largest research center in Canada, the largest cardiovascular prevention center in the country, and the largest cardiovascular genetics center in Canada. The Institute is affiliated with the Université de Montréal and has more than 2,000 employees, including 245 doctors and more than 85 researchers. icm-mhi.org About the Montreal Health Innovations Coordinating Center (MHICC)The Montreal Health Innovations Coordinating Center (MHICC) is a leading academic clinical research organization and an integral part of the Montreal Heart Institute (MHI). The MHICC possesses an established network of collaborators in over 4,500 clinical sites in more than 35 countries. It has specific expertise in precision medicine, low-cost high-quality clinical trials, and drug repurposing. mhicc.org About PharmascienceFounded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec. With its head office located in Montreal and its 1,500 employees, Pharmascience Inc. is a private pharmaceutical company with deep roots in Canada, and whose global reach spans across more than 60 countries. Ranked 47th among the top 100 Canadian investors in Research and Development (R&D), thanks to $49,5 million investment in 2018, Pharmascience Inc. is one of the largest manufacturer of generic drugs in the country. pharmascience.com About CGIFounded in 1976, CGI is one of the world’s largest information technology (IT) and management consulting firms. From hundreds of locations around the world, CGI offers a complete portfolio of services and solutions: strategic IT and management consulting services, systems integration services, intellectual property solutions as well as IT and business process management services in delegated mode. cgi.com/canada About DacimaFounded in 2006, Dacima Software Inc. is a leading innovator in Electronic Data Capture (EDC) software for clinical research. Dacima’s EDC software, Dacima Clinical Suite, is a fully feature EDC software application with integrated modules for patient randomization (IWRS), supply management, ePRO, eDiary, medical coding and eConsent. Dacima’s flexible and highly configurable EDC platforms allow for the design of all types of study designs including clinical trials, patient registries, observational studies and web surveys through an intuitive user-friendly web interface. dacimasoftware.com About the COVID-19 Therapeutics AcceleratorThe Therapeutics Accelerator is an initiative launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard with support from public and philanthropic donors to speed up the response to the COVID-19 pandemic by identifying, assessing, developing, and scaling up treatments. Its partners are committed to equitable access, including making products available and affordable in low-resource settings. https://www.therapeuticsaccelerator.org/ Media Contacts:Camille TurbideCamille.firstname.lastname@example.orgCanada : + 514 755-5354Europe : +33 07 85 95 11 29 United StatesChristy Maginnchristymmaginn@msn.com+ 1 703 297-7194
Here's why scientists are concerned.
According to reports by the Wall Street Journal and Bloomberg, NBC Sports Group Chairman Pete Bevacqua told staffers in a memo that the NBC Sports Network cable channel is shutting down the end of this year. While it’s unclear what will happen to some of the content it currently airs, stuff like NHL games and NASCAR races will shift to the USA Network channel instead, and they plan to dual-broadcast some of those prior to the channel going dark. This could also push some content to NBCUniversal’s streaming platform Peacock, but the focus right away seems to be strengthening USA Network as an option against channels like Warner’s TNT/TBS.
TULSA, Okla. and VANCOUVER, British Columbia, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Jericho Oil Corporation (“Jericho”) (TSX-V: JCO; OTC PINK: JROOF) is pleased to announce that it is has entered into an agreement for the acquisition of all the assets of Hydrogen Technologies Inc. (“HTI”). HTI holds robust intellectual property for a breakthrough high-temperature Dynamic Combustion Chamber (“DCC”) boiler that enables zero-emissions hydrogen to generate heat, hot-water, high-temperature steam, and Combined Heat & Power (“CHP”) through a closed-loop process. The closing of the acquisition remains subject to the approval of the TSX Venture Exchange and also the approval of the shareholders of HTI. HTI’s patented zero emissions DCC boiler system aims to decarbonize the nearly $30 billion global commercial and industrial heating industry while providing best-in-class energy efficiencies. The traditional water heating, steam generation and CHP market has been powered by fossil fuel for over 100 years, producing harmful Carbon Dioxide (CO2), nitrogen oxides (NOx) and sulfur dioxide (SO2) emissions which are increasingly being phased out or eliminated through government-led emission-based performance standards worldwideGlobally, 85% of all Industrial Boilers emit harmful greenhouse gas emissions (GHG) with over 35% of the Industrial Boiler install base still powered by coalCritically, 37% of all fossil fuels utilized in US Industry today are burned to produce steam, with all the major industrial energy users devoting significant proportions of their fossil fuel consumption to steam production: food processing (57%), pulp and paper (81%), chemicals (42%), petroleum refining (23%) and primary metals (10%) Steam is used in 80% of the electrical generation in the US HTI’s DCC can be used for a variety of commercial and industrial applications, generating zero emission electricity when combined with a turbine genset in CHP applications. The patented DCC technology: Awarded the Solar Impulse Efficient Solutions Label in 2019Requires no air permit, with water as the only by-productEliminates all NOx, SOx and CO2 emissions through a closed-loop combustion processProduces at a 30% greater efficiency than traditional fossil fuel boilers with a 97% overall boiler thermal efficiencyCritically, the Total Cost of Production ($ / lb steam) is cost competitive to traditional hydrocarbon boiler systems There are large commercial and industrial (“C&I”) markets which HTI is specifically targeting with their zero emissions DCC Hydrogen Boiler. According to market research, the C&I market for boilers represents a $30 billion annual market and is estimated to grow between 5 to 7% per year, over the next seven years, with low and zero carbon solutions expected to outpace: Commercial markets for heat or hot water as an end-use: Shopping malls, universities and institutions, airports, hotels, stadiums, hospitals, and government buildingsIndustrial markets for steam-generation as an industrial process end-use: refining and petrochemical, pulp and paper, chemical and pharmaceutical, food processing, refrigeration, metals, and mining among othersFor Combined Heat & Power applications: Utility Power Generation, Energy Storage, On-Site Distributed Energy, and Data Centers will be critical markets for a zero-emissions DCC solution As a part of the transaction, Jericho will also be acquiring the highly dedicated and robust technical team from HTI including its founder, Ed Stockton and President, Janet Reiser. Adding Ed’s technical capabilities and expertise related to the hydrogen market will allow for a seamless transition in building up the DCC boiler’s commercial success within our low-carbon energy portfolio. Prior to founding HTI in 2005, Ed spent most of his career with Florida Power & Light (now NextEra Energy) focused on low-carbon technologies with direct power plant experience, including equipment startup, maintenance, due diligence, government relations and regulation promulgation. Janet, with over 35 years of experience in energy management and engineering, most recently running the governmental Alaska Energy Authority, will continue to lead HTI’s day-to-day operations and sales efforts. As consideration for the technology acquisition, Jericho will deliver to HTI, 6,700,000 shares of Jericho Common Stock. The Shares will be restricted pursuant to agreed upon milestones related to commercial deployment and technological successes. Jericho will pay the out-of-pocket costs associated with the transaction on behalf of HTI and winding up their entity. Brian Williamson, CEO of Jericho Oil Corporation, states, “We are excited to announce the acquisition of HTI’s patented and novel zero emission hydrogen technology and welcome their world class team. The world is increasingly demanding a transition away from traditional energy sources to low carbon solutions – HTI’s hydrogen solution expands our portfolio to include a technology that will transition one of the largest carbon emitters to a zero-emission energy source. We look forward to receiving the exchanges final approval and updating our shareholders accordingly on our go-forward energy portfolio strategy.” Separate from the transaction, Jericho also announces that it has granted incentive stock options (the “Options”), pursuant to its stock option plan (the “Plan”), of 700,000 common shares of the Company, to certain directors and officers of the Company. The Options are exercisable at a price of $0.45 CAD for a period of up to 5 years. This news release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only Jericho's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Jericho's control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur" or "will be achieved". Although Jericho believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. Forward-looking information and statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information and statements which include, but are not limited to: the effects of and risks associated with the ongoing COVID-19 pandemic, the impact of general economic conditions, industry conditions and current and future commodity prices including sustained low oil prices, significant and ongoing stock market volatility, currency and interest rates, governmental regulation of the oil and gas industry, including environmental regulation; geological, technical and drilling problems; unanticipated operating events; competition for and/or inability to retain drilling rigs and other services; the availability of capital on acceptable terms; the need to obtain required approvals from regulatory authorities; liabilities inherent in oil and gas exploration, development and production operations; and the other factors described in our public filings available at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive. The forward-looking information and forward-looking statements contained in this news release are made as of the date of this news release, and Jericho does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. CONTACT: Adam Rabiner Director, Investor Relations604.email@example.com
Fresh after two weeks without a competitive fixture, Wellington are desperate for their first A-League win against last-placed Newcastle.
NEW ORLEANS, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Boston Scientific Corporation (BSX) Class Period: 4/24/2019 - 11/16/2020Lead Plaintiff Motion Deadline: February 2, 2021SECURITIES FRAUD To learn more, visit https://www.ksfcounsel.com/cases/nyse-bsx/ Splunk Inc. (SPLK) Class Period: 10/21/2020 - 12/2/2020Lead Plaintiff Motion Deadline: February 2, 2021SECURITIES FRAUD To learn more, visit https://www.ksfcounsel.com/cases/nasdaqgs-splk/ If you purchased shares of the above companies and would like to discuss your legal rights and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner, Lewis Kahn, toll-free at 1-877-515-1850, via email (Lewis.Kahn@KSFcounsel.com), or via the case links above. If you wish to serve as a Lead Plaintiff in the class action, you must petition the Court on or before the Lead Plaintiff Motion deadline. About KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking to recover investment losses due to corporate fraud and malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana. To learn more about KSF, you may visit www.ksfcounsel.com. Contact: Kahn Swick & Foti, LLCLewis Kahn, Managing Partnerlewis.firstname.lastname@example.org Poydras St., Suite 3200New Orleans, LA 70163
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Amyris, Inc. (NasdaqGS: AMRS).
NEW ORLEANS, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: SolarWinds Corporation (SWI)Class Period: 2/24/2020 - 12/15/2020Lead Plaintiff Motion Deadline: March 5, 2021SECURITIES FRAUDTo learn more, visit https://www.ksfcounsel.com/cases/nyse-swi/ QuantumScape Corporation (QS)Class Period: 11/27/2020 - 12/31/2020Lead Plaintiff Motion Deadline: March 8, 2021SECURITIES FRAUDTo learn more, visit https://www.ksfcounsel.com/cases/nyse-qs/ Penumbra, Inc. (PEN)Class Period: 8/3/2020 - 12/15/2020Lead Plaintiff Motion Deadline: March 16, 2021SECURITIES FRAUDTo learn more, visit https://www.ksfcounsel.com/cases/nyse-pen/ If you purchased shares of the above companies and would like to discuss your legal rights and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner, Lewis Kahn, toll-free at 1-877-515-1850, via email (Lewis.Kahn@KSFcounsel.com), or via the case links above. If you wish to serve as a Lead Plaintiff in the class action, you must petition the Court on or before the Lead Plaintiff Motion deadline. AboutKSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking to recover investment losses due to corporate fraud and malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana. To learn more about KSF, you may visit www.ksfcounsel.com. Contact: Kahn Swick & Foti, LLCLewis Kahn, Managing Partnerlewis.email@example.com Poydras St., Suite 3200New Orleans, LA 70163
A boomerang handcrafted by a South Australian Indigenous leader has been taken into space aboard a NASA-operated Tesla rocket.
On the anniversary of the world's first coronavirus lockdown, in the Chinese city of Wuhan, life for animal lover Du Fan has returned to something like normal. That means Du and his organisation, the Wuhan Small Animals Protection Association, can focus their energy on rescuing, caring and finding homes for stray cats and dogs. Twelve months ago, however, Du, 38, and his group were faced with a whole new problem - saving pets who had homes, but whose owners were unable to provide them with daily necessities when the city where the coronavirus emerged went into lockdown.
The Nets have allowed 272 points in 2 games against the Cavs, one of the worst offenses in the NBA.
A Queensland politician has taken a stunning swipe at Indigenous cricketer Dan Christian's Australia Day comments.
Trainers Anthony and Sam Freedman will weigh up whether to put Artorius on a Blue Diamond path after he demolished his rivals to score at Sandown.
She described the news as an "early birthday present".
Sri Lanka vs England, second Test: live scoreboard in full James Anderson proves his indispensability with guile and bounce in Galle Gutsy Mark Wood fights back to get England rewards after sweltering day in Galle
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Cabot Oil & Gas Corporation (NYSE: COG).
The Freestanding Playground Equipment Market will grow by $ 2.01 bn during 2021-2025
The woman will be paid about A$19,000 due to her experience as she ordered a matcha tea latte at Starbucks last year.
IRVINE, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Plutos Sama Holdings, Inc. (PSH), today filed for injunctive relief to prevent the purported sale of Jagex Limited which is an online gaming company based in Irvine, California and Cambridge, England and to enforce its rights to its auction win in September of 55% of Jagex and its parent company from seller Huarong Trust. The case was filed in Federal Court in California on January 21, 2021 and is captioned Plutos Sama Holdings, Inc v. Jagex et al case # Case 8:21-cv-00133 and names Jagex as well as its holding company and several Trust companies in China that were selling the asset. FOR MEDIA CONTACT: firstname.lastname@example.org Plutos Sama Holdings, Inc.Plutos Sama Holdings, Inc. is a private equity company in the business of taking control positions in domestic and international distressed and contentious residential and commercial real estate ventures, micro-lending, securitizations, law firms, restaurants, mortgage servicing platforms, and eSports.For more information, visit www.plutosholdings.com. Certain information set forth in this presentation contains “forward-looking information”, including “future oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, information contained herein constitutes forward-looking statements of the Company including with respect to future M&A activity and global growth and completion of the Company’s and its partners projects including any required approvals from the regulatory bodies governing sale and shareholder ratification that are currently underway, in development or otherwise under consideration. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.
Chris "Pineapple" Hooper is one of 17 candidates vying for the Rockhampton mayoralty after changes to how council vacancies are filled were rushed through.